Risk of triple-class virological failure in children with HIV: a retrospective cohort study
Identifieur interne : 003C16 ( Main/Merge ); précédent : 003C15; suivant : 003C17Risk of triple-class virological failure in children with HIV: a retrospective cohort study
Auteurs :Source :
- Lancet [ 0140-6736 ] ; 2011.
Abstract
In adults with HIV treated with antiretroviral drug regimens from within the three original drug classes (nucleoside or nucleotide reverse transcriptase inhibitors [NRTIs], non-NRTIs [NNRTIs], and protease inhibitors), virological failure occurs slowly, suggesting that long-term virological suppression can be achieved in most people, even in areas where access is restricted to drugs from these classes. It is unclear whether this is the case for children, the group who will need to maintain viral suppression for longest. We aimed to determine the rate and predictors of triple-class virological failure to the three original drugs classes in children.
In the Collaboration of Observational HIV Epidemiological Research Europe, the rate of triple-class virological failure was studied in children infected perinatally with HIV who were aged less than 16 years, starting antiretroviral therapy (ART) with three or more drugs, between 1998 and 2008. We used Kaplan-Meier and Cox regression methods to investigate the risk and predictors of triple-class virological failure after ART initiation.
Of 1007 children followed up for a median of 4·2 (IQR 2·4–6·5) years, 237 (24%) were triple-class exposed and 105 (10%) had triple-class virological failure, of whom 29 never had a viral-load measurement less than 500 copies per mL. Incidence of triple-class virological failure after ART initiation increased with time, and risk by 5 years after ART initiation was 12·0% (95% CI 9·4–14·6). In multivariate analysis, older age at ART initiation was associated with increased risk of failure (p=0·02). Of 686 children starting ART with NRTIs and either a NNRTI or ritonavir-boosted protease inhibitor, the rate of failure was higher than in adults with heterosexually transmitted HIV (hazard ratio 2·2 [95% CI 1·6–3·0, p<0·0001]).
Findings highlight the challenges of attaining long-term viral suppression in children who will be taking life-long ART. Early identification of children not responding to ART, adherence support, particularly for children and adolescents aged 13 years or older starting ART, and ART simplification strategies are all needed to attain and sustain virological suppression.
Url:
DOI: 10.1016/S0140-6736(11)60208-0
PubMed: 21511330
PubMed Central: 3099443
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 002770
- to stream Pmc, to step Curation: 002769
- to stream Pmc, to step Checkpoint: 002101
- to stream Ncbi, to step Merge: 001280
- to stream Ncbi, to step Curation: 001280
- to stream Ncbi, to step Checkpoint: 001280
Links to Exploration step
PMC:3099443Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Risk of triple-class virological failure in children with HIV: a retrospective cohort study</title>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">21511330</idno>
<idno type="pmc">3099443</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3099443</idno>
<idno type="RBID">PMC:3099443</idno>
<idno type="doi">10.1016/S0140-6736(11)60208-0</idno>
<date when="2011">2011</date>
<idno type="wicri:Area/Pmc/Corpus">002770</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002770</idno>
<idno type="wicri:Area/Pmc/Curation">002769</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">002769</idno>
<idno type="wicri:Area/Pmc/Checkpoint">002101</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002101</idno>
<idno type="wicri:Area/Ncbi/Merge">001280</idno>
<idno type="wicri:Area/Ncbi/Curation">001280</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001280</idno>
<idno type="wicri:Area/Main/Merge">003C16</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Risk of triple-class virological failure in children with HIV: a retrospective cohort study</title>
</analytic>
<series><title level="j">Lancet</title>
<idno type="ISSN">0140-6736</idno>
<idno type="eISSN">1474-547X</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><title>Summary</title>
<sec><title>Background</title>
<p>In adults with HIV treated with antiretroviral drug regimens from within the three original drug classes (nucleoside or nucleotide reverse transcriptase inhibitors [NRTIs], non-NRTIs [NNRTIs], and protease inhibitors), virological failure occurs slowly, suggesting that long-term virological suppression can be achieved in most people, even in areas where access is restricted to drugs from these classes. It is unclear whether this is the case for children, the group who will need to maintain viral suppression for longest. We aimed to determine the rate and predictors of triple-class virological failure to the three original drugs classes in children.</p>
</sec>
<sec><title>Methods</title>
<p>In the Collaboration of Observational HIV Epidemiological Research Europe, the rate of triple-class virological failure was studied in children infected perinatally with HIV who were aged less than 16 years, starting antiretroviral therapy (ART) with three or more drugs, between 1998 and 2008. We used Kaplan-Meier and Cox regression methods to investigate the risk and predictors of triple-class virological failure after ART initiation.</p>
</sec>
<sec><title>Findings</title>
<p>Of 1007 children followed up for a median of 4·2 (IQR 2·4–6·5) years, 237 (24%) were triple-class exposed and 105 (10%) had triple-class virological failure, of whom 29 never had a viral-load measurement less than 500 copies per mL. Incidence of triple-class virological failure after ART initiation increased with time, and risk by 5 years after ART initiation was 12·0% (95% CI 9·4–14·6). In multivariate analysis, older age at ART initiation was associated with increased risk of failure (p=0·02). Of 686 children starting ART with NRTIs and either a NNRTI or ritonavir-boosted protease inhibitor, the rate of failure was higher than in adults with heterosexually transmitted HIV (hazard ratio 2·2 [95% CI 1·6–3·0, p<0·0001]).</p>
</sec>
<sec><title>Interpretation</title>
<p>Findings highlight the challenges of attaining long-term viral suppression in children who will be taking life-long ART. Early identification of children not responding to ART, adherence support, particularly for children and adolescents aged 13 years or older starting ART, and ART simplification strategies are all needed to attain and sustain virological suppression.</p>
</sec>
<sec><title>Funding</title>
<p><funding-source id="GS1">UK Medical Research Council</funding-source>
award G0700832.</p>
</sec>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Judd, A" uniqKey="Judd A">A Judd</name>
</author>
<author><name sortKey="Doerholt, K" uniqKey="Doerholt K">K Doerholt</name>
</author>
<author><name sortKey="Tookey, Pa" uniqKey="Tookey P">PA Tookey</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Brady, Mt" uniqKey="Brady M">MT Brady</name>
</author>
<author><name sortKey="Oleske, Jm" uniqKey="Oleske J">JM Oleske</name>
</author>
<author><name sortKey="Williams, Pl" uniqKey="Williams P">PL Williams</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Demartino, M" uniqKey="Demartino M">M deMartino</name>
</author>
<author><name sortKey="Tovo, Pa" uniqKey="Tovo P">PA Tovo</name>
</author>
<author><name sortKey="Balducci, M" uniqKey="Balducci M">M Balducci</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Sharland, M" uniqKey="Sharland M">M Sharland</name>
</author>
<author><name sortKey="Blanche, S" uniqKey="Blanche S">S Blanche</name>
</author>
<author><name sortKey="Castelli, G" uniqKey="Castelli G">G Castelli</name>
</author>
<author><name sortKey="Ramos, J" uniqKey="Ramos J">J Ramos</name>
</author>
<author><name sortKey="Gibb, Dm" uniqKey="Gibb D">DM Gibb</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Violari, A" uniqKey="Violari A">A Violari</name>
</author>
<author><name sortKey="Cotton, Mf" uniqKey="Cotton M">MF Cotton</name>
</author>
<author><name sortKey="Gibb, Dm" uniqKey="Gibb D">DM Gibb</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Goetghebuer, T" uniqKey="Goetghebuer T">T Goetghebuer</name>
</author>
<author><name sortKey="Haelterman, E" uniqKey="Haelterman E">E Haelterman</name>
</author>
<author><name sortKey="Le Chenadec, J" uniqKey="Le Chenadec J">J Le Chenadec</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Welch, S" uniqKey="Welch S">S Welch</name>
</author>
<author><name sortKey="Sharland, M" uniqKey="Sharland M">M Sharland</name>
</author>
<author><name sortKey="Lyall, Eg" uniqKey="Lyall E">EG Lyall</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Paterson, Dl" uniqKey="Paterson D">DL Paterson</name>
</author>
<author><name sortKey="Swindells, S" uniqKey="Swindells S">S Swindells</name>
</author>
<author><name sortKey="Mohr, J" uniqKey="Mohr J">J Mohr</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Nachega, Jb" uniqKey="Nachega J">JB Nachega</name>
</author>
<author><name sortKey="Hislop, M" uniqKey="Hislop M">M Hislop</name>
</author>
<author><name sortKey="Dowdy, Dw" uniqKey="Dowdy D">DW Dowdy</name>
</author>
<author><name sortKey="Chaisson, Re" uniqKey="Chaisson R">RE Chaisson</name>
</author>
<author><name sortKey="Regensberg, L" uniqKey="Regensberg L">L Regensberg</name>
</author>
<author><name sortKey="Maartens, G" uniqKey="Maartens G">G Maartens</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Bangsberg, Dr" uniqKey="Bangsberg D">DR Bangsberg</name>
</author>
<author><name sortKey="Kroetz, Dl" uniqKey="Kroetz D">DL Kroetz</name>
</author>
<author><name sortKey="Deeks, Sg" uniqKey="Deeks S">SG Deeks</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Deeks, Sg" uniqKey="Deeks S">SG Deeks</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Reddington, C" uniqKey="Reddington C">C Reddington</name>
</author>
<author><name sortKey="Cohen, J" uniqKey="Cohen J">J Cohen</name>
</author>
<author><name sortKey="Baldillo, A" uniqKey="Baldillo A">A Baldillo</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Martin, S" uniqKey="Martin S">S Martin</name>
</author>
<author><name sortKey="Elliott Desorbo, Dk" uniqKey="Elliott Desorbo D">DK Elliott-DeSorbo</name>
</author>
<author><name sortKey="Wolters, Pl" uniqKey="Wolters P">PL Wolters</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Murphy, Da" uniqKey="Murphy D">DA Murphy</name>
</author>
<author><name sortKey="Belzer, M" uniqKey="Belzer M">M Belzer</name>
</author>
<author><name sortKey="Durako, Sj" uniqKey="Durako S">SJ Durako</name>
</author>
<author><name sortKey="Sarr, M" uniqKey="Sarr M">M Sarr</name>
</author>
<author><name sortKey="Wilson, Cm" uniqKey="Wilson C">CM Wilson</name>
</author>
<author><name sortKey="Muenz, Lr" uniqKey="Muenz L">LR Muenz</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Menson, En" uniqKey="Menson E">EN Menson</name>
</author>
<author><name sortKey="Walker, As" uniqKey="Walker A">AS Walker</name>
</author>
<author><name sortKey="Sharland, M" uniqKey="Sharland M">M Sharland</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Havens, Pl" uniqKey="Havens P">PL Havens</name>
</author>
<author><name sortKey="Gibb, Dm" uniqKey="Gibb D">DM Gibb</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Kjaer, J" uniqKey="Kjaer J">J Kjaer</name>
</author>
<author><name sortKey="Ledergerber, B" uniqKey="Ledergerber B">B Ledergerber</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Walker, As" uniqKey="Walker A">AS Walker</name>
</author>
<author><name sortKey="Doerholt, K" uniqKey="Doerholt K">K Doerholt</name>
</author>
<author><name sortKey="Sharland, M" uniqKey="Sharland M">M Sharland</name>
</author>
<author><name sortKey="Gibb, Dm" uniqKey="Gibb D">DM Gibb</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Johnson, Va" uniqKey="Johnson V">VA Johnson</name>
</author>
<author><name sortKey="Brun Vezinet, F" uniqKey="Brun Vezinet F">F Brun-Vezinet</name>
</author>
<author><name sortKey="Clotet, B" uniqKey="Clotet B">B Clotet</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Kekitiinwa, A" uniqKey="Kekitiinwa A">A Kekitiinwa</name>
</author>
<author><name sortKey="Lee, Kj" uniqKey="Lee K">KJ Lee</name>
</author>
<author><name sortKey="Walker, As" uniqKey="Walker A">AS Walker</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Giaquinto, C" uniqKey="Giaquinto C">C Giaquinto</name>
</author>
<author><name sortKey="Morelli, E" uniqKey="Morelli E">E Morelli</name>
</author>
<author><name sortKey="Fregonese, F" uniqKey="Fregonese F">F Fregonese</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Mills, Ej" uniqKey="Mills E">EJ Mills</name>
</author>
<author><name sortKey="Nachega, Jb" uniqKey="Nachega J">JB Nachega</name>
</author>
<author><name sortKey="Buchan, I" uniqKey="Buchan I">I Buchan</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Ledergerber, B" uniqKey="Ledergerber B">B Ledergerber</name>
</author>
<author><name sortKey="Lundgren, Jd" uniqKey="Lundgren J">JD Lundgren</name>
</author>
<author><name sortKey="Walker, As" uniqKey="Walker A">AS Walker</name>
</author>
</analytic>
</biblStruct>
</listBibl>
</div1>
</back>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003C16 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 003C16 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= SidaSubSaharaV1 |flux= Main |étape= Merge |type= RBID |clé= PMC:3099443 |texte= Risk of triple-class virological failure in children with HIV: a retrospective cohort study }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:21511330" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \ | NlmPubMed2Wicri -a SidaSubSaharaV1
![]() | This area was generated with Dilib version V0.6.32. | ![]() |